Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

Title: Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

Volume: 4 Issue: 3

Author(s): Michael C. Heinrich

Affiliation:

Keywords: flt3, tyrosine kinase, kinase inhibitor, aml, pdgfr

Abstract: Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

Cite this article as:

Heinrich C. Michael, Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects, Mini-Reviews in Medicinal Chemistry 2004; 4 (3) . https://dx.doi.org/10.2174/1389557043487394